Exact Sciences stock crashed Wednesday after the company inked a deal for the exclusive eights to Freenome's blood-based ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Full-year 2025 revenue and adjusted EBITDA guidance were raised, reflecting strong commercial execution and new product launches. These 10 stocks could mint the next wave of millionaires › Exact ...

Easy at-home tests for colon cancer, including FIT and Cologuard, offer alternatives to traditional colonoscopies for early detection and prevention.

Exact Sciences’ gross margin for the quarter was 69%, with adjusted gross margin at 72%. The company reported operating cash flow of $89 million and free cash flow of $47 million, ending the quarter ...

Madison-based Exact Sciences is cutting about 4% of its overall workforce, impacting about 200 positions in Wisconsin.

Cologuard is easy for patients to use and easy for doctors to interpret the results, said Dr. Casey Allen, a surgical oncologist at Allegheny Health Network in Pennsylvania.

A decade ago, Exact Sciences launched Cologuard, impacting the fight against colorectal cancer. Its growth of 7000% is in part due to a focus on consumerization.

The Forbes article also states Cologuard has an 8 percent false-negative rate and a 13 percent false-positive rate Becker’s ASC Review asked three gastroenterologists for their thoughts on Cologuard.

The Cologuard can say that you have an abnormality when a colonoscopy would indicate normal. For 45% of people with a positive Cologuard test, no abnormalities will be found upon colonoscopy.

Here, two gastroenterologists share their thoughts on Cologuard: Harish Gagneja, MD, gastroenterologist at Austin (Texas) Gastroenterology: I don’t recommend Cologuard as a first-line test because: ...